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Introduction
Stem cells have an ever-increasing number of applications 
in the ﬁ eld of regenerative medicine. Th ey can now be 
used to treat many diseases or conditions by replacing 
and restoring the function of cells, tissues or organs in 
order to establish normal function [1]. Th e sources of 
stem cells further extend the number of therapeutic 
applications; this is combined with stem cell research, 
steadily moving from the bench-top towards clinical 
applications. Stem cells have the ability to migrate within 
tissues and on substrates, which is often guided by the 
presence of chemical mediators and topography [2]. Th e 
migration of these cells to and from the target location 
requires monitoring to determine the eﬀ ectiveness of the 
therapy. It is highly desirable to have a multifunctional 
mechanism for targeting, tracking and stimulating stem 
cells both in vivo and in vitro; this can be achieved 
through the use of nanoparticles [3]. Th e use of 
nanoparticles can provide answers to questions such as: 
What is the optimal delivery route? What is the extent of 
engraftment? What are the migratory patterns post 
transplantation? What is the ideal dosage scheme? 
Having the answer to these questions will help in the 
optimisation of the overall therapy and thus in increasing 
its therapeutic potential [4]. A technique that is capable 
of providing these answers would be very important to 
the ﬁ eld of tissue engineering; the use of magnetic 
nanoparticles (MNPs) is potentially a suitable method.
In a broad context, we see that the application of 
nanotechnology within the remit of stem cell therapeutics 
is increasing. Research has already been undertaken 
using various nanoscale materials, including nano-
particles (both metallic/magnetic and ceramic), nano-
ﬁ bres and carbon nanotubes, amongst others [5]. Th e 
major beneﬁ t of using nanoparticles is that, due to their 
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size, they have the unique ability to be in close proximity 
to a speciﬁ c biological entity or marker [6] and interact 
with it on a cellular (10 to 100  μm), subcellular (20 to 
250 nm), protein (3 to 50 nm) or genetic (10 to 100 nm) 
scale [7,8]. MNPs speciﬁ cally have a multifunctional 
aspect within this ﬁ eld, where they can be used in the 
tagging, tracking and activation of stem cells both in vitro 
and in vivo. Th is multifunctional propensity with relation 
to orthopaedic therapies will be the main focus of the 
present review.
Magnetic nanoparticles
MNPs have traditionally been used for a number of bio-
medical applications, including cell separation, auto-
mated DNA extraction, gene targeting, drug delivery, 
diagnostics and hyperthermia [9,10]. However, there are 
far more diverse applications, as shown by their employ-
ment in the ﬁ eld of regenerative medicine; for example, 
cell transfection and magnetic-force stimulation of cells 
[11].
In general, nanoparticles can be generated by a number 
of methods, depending on the material to be used, but 
include co-precipitation, microemulsions, thermal de com-
po sition, metal-reducing bacteria and the use of polyols 
[6,9,10], and are manufactured from a range of synthetic 
or biological materials – for example, lipo somes, 
polymer, protein, dendrimers, biodegradable poly mer 
nanoparticles and carbon-based nanoparticles, and 
MNPs [12]. A number of metals such as nickel, cobalt 
and iron can be used to convey the magnetic properties 
of these MNPs. Th e behaviour of the MNP within an 
applied magnetic ﬁ eld depends on a number of factors 
directly related to the properties of the MNP, such as size 
[13] and magnetisation [14]. When considering MNPs 
for bio medical application, the toxic nature of the 
particles must also be investigated thoroughly and 
clinical trials have to be performed to further assess this 
aspect [15]. It has been found that certain metals, cobalt 
and nickel for example, are toxic to biological entities and 
therefore not suitable for biomedical applications, while 
others such as iron-oxide-based particles are considered 
safer [16,17].
Magnetic materials are commonly classiﬁ ed according 
to their susceptibility to magnetic ﬁ elds. Paramagnetic 
substances are only magnetised when exposed to a 
magnetic ﬁ eld, while ferromagnetic materials remain 
magne tised even after the magnetic ﬁ eld has been 
removed [16]. Importantly, ferromagnetic materials 
develop paramagnetic properties as they decrease in size 
to approximately 20 nm in diameter, or 3 nm in the case 
of pure iron beads [6,18]. Th is implies that once the 
magnetic ﬁ eld has been removed the particles are no 
longer magnetic while still maintaining a higher satura-
tion magnetism than paramagnetic materials, and so are 
named superparamagnetic. For the biomedical applica-
tion of MNPs, particles exhibiting superpara magnetic 
properties are preferred as this implies that the particles 
will not be attracted to each other and so the risk of 
agglomeration in a medical setting is minimised [19]. In 
addition, the biocompatible and low-toxic nature of the 
particles is highly advantageous [17]. Particles possessing 
these properties are known as superpara magnetic iron 
oxide nanoparticles (SPIONs).
As previously mentioned, MNPs can be coated with 
organic/inorganic polymers to improve their biocompati-
bility. Th ese include proteins or ligands such as RGD, 
ﬁ bronectin, collagen type I, poly-l-lysine and dextran 
[10]. Surface coatings can be customised and designed 
according to speciﬁ c needs by altering surface charges, 
protein binding capacity, surface topography and 
biocompatibility [20]. Th is further functionalises the 
particles, allowing them to interact with the cell for 
tagging and targeting of biological entities with minimal 
toxic eﬀ ects [7,21].
Iron oxide nanoparticles
Iron oxide MNPs can be categorised by size: ultra-small 
SPIONs, which are approximately 10 to 40 nm in diameter 
[22]; monocrystalline iron oxide nanoparticles, which are 
a subcategory of ultra-small SPIONs, charac terised by 
the crystalline state of their core (typically 10 to 30 nm in 
diameter) [23]; SPIONs, approximately 50 to 200 nm in 
diameter; and, ﬁ nally, microparamagnetic iron oxide 
particles, which are approximately 300 nm to 3.5 μm in 
diameter [24,25]. SPIONs are typically composed of either 
a magnetite (Fe3O4) or maghemite (γ-Fe2O3) core [26] 
coated with an organic/inorganic polymer [27] or preci pi-
tated through out a porous biocompatible polymer [14].
Th e precedent for using SPIONs in a biological setting 
comes from the application of SPION-based magnetic 
resonance imaging (MRI) contrast agents [16]. It is 
thought that these contrast agents can be used for a 
variety of purposes in the clinical translation of stem-
cell-based therapies for the tagging, tracking and activa-
tion of stem cells and other cell lines [28,29]. Feridex 
(Berlex Biosciences, Richmond, VA, USA), or Endorem in 
Europe (Guerbet, Sulzbach, Germany), are examples of 
FDA-approved, iron-based MRI contrast agents, but have 
unfortunately recently been taken oﬀ  the market [30].
Importance of the use MNPs in stem cell therapy in 
orthopaedics
Traditionally, severe orthopaedic medical conditions 
have been treated surgically by the insertion of artiﬁ cial 
implants or tissue grafts to restore the function of the 
damaged tissue. However, implant failure, immune rejec-
tion, limited supply and donor site morbidity are issues 
requiring attention. Regenerative medicine oﬀ ers an 
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alternative therapeutic approach to meeting a vast pro-
por tion of orthopaedic needs [31]. Mesenchymal stem 
cells (MSCs) are a multipotent cell source that has shown 
tremendous promise in the regeneration of connective 
tissue, including cartilage, bone, tendon and muscle [32]. 
Th e combination of stem cells with materials science 
therefore provides a strong opportunity for therapeutic 
advances [33]. Regenerative medicine has commonly 
been used in the therapeutic treatment of osteoarthritis, 
a disease that aﬀ ects 8.5 million people in the UK alone. 
Osteoarthritis is characterised by the destruction of the 
synovial joint [34]. Surgical techniques range from simple 
pain management (lavage and debridement) to total knee 
replacement. However, this therapy is limited by implant 
failure and is restricted to patients over the age of 60 due 
to the limited lifespan of the implant [33]. Autologous 
chondrocyte implantation has therefore been developed, 
involving isolation, in vitro expansion and subsequent 
reimplantation of autologous articular chondrocytes into 
the defect site [31,33]. Tissue engineering has also proven 
promising in the treatment of herniated intervertebral 
discs with the applications of autologous disc cells [34].
Although these therapies have been successful in the 
short term, the long-term prognosis of the treatment, 
although optimistic, is mixed [31,35]. In response to this, 
it has become necessary to assess the in vivo parameters 
associated with these therapies, in order to accurately 
gauge the success of these cellular therapies, particularly 
in the long term [36]. Evaluation of the short-term and 
long-term survival of the cells, the rate of repair and the 
number of cells remaining (or migrating to/from) the 
desired location (biodistribution) post transplantation is 
useful in evaluating therapeutic performance [30] but 
extensive evaluation of eﬃ  cacy and safety is still to be 
conducted [12]. Th ere is evidence to suggest that loading 
of SPIONs with drugs can actually reduce the toxicity of 
drugs; for example, doxorubicin by association with 
thermally cross-linked SPIONs (Dox@TCL-SPIONs) [37]. 
In addition, a recent review highlights that cytotoxicity 
studies using MNPs or various types and forms (for 
example, quantum dots) are conducted at concentrations 
often not relevant to a clinical scenario, and as a result 
discourage further testing and limit the belief in clinical 
applicability of the technology [12]. It is noteworthy that 
heavy metal ions within particles such as quantum dots 
are the main tributary to cyto toxicity [38].
Th e biodistribution of cells is dependent on a number 
of factors; that is, the site of implantation, target organ, 
mode of delivery and cell type [39]. Ultimately, quanti-
tation of these factors is essential for optimisation of cell 
delivery methods and dosage schemes [40]. Traditionally, 
this has been done by carrying out histological and 
immunohistochemical tests [41-43], which require the 
termination of an experiment to collect tissue samples for 
assessment. Long-term follow-up of the therapy is there-
fore impossible and may require extensive use of animals 
for in vivo models [41,44,45]. Th is highlights the impor-
tance of a non-invasive technique that will contribute to 
the accurate and reproducible evaluation of the success 
of therapy [13,45,46]. It is thought that a great deal of in 
vivo information can be gathered through the use of 
MNP technologies, thus optimising not only these 
therapies but also the large portfolio of orthopaedic cell-
based therapies [46]. Th e typical schema for the in vivo 
therapeutic appli cations overall is indicated in Figure  1; 
the use of SPIONs in regenerative medicine and tissue 
engineering purposes will be highlighted.
Labelling of stem cells with SPIONs
Labelling agents should be biocompatible, nontoxic and 
should not aﬀ ect the diﬀ erentiation state of stem cells or 
their multipotency/pluripotency; they must have the 
potential to be detected and monitored; and, ﬁ nally, they 
must be versatile enough to be adapted to various cell 
types, including MSCs [47]. As previously mentioned, 
the association of SPIONs with stem cells oﬀ ers an 
attractive method for tracking, targeting and controlling 
cells [48]. Broadly speaking, this association is achieved 
through either the internalisation of SPIONs or the 
binding of SPIONS to cell surface markers (for example, 
integrins) or to speciﬁ c antibodies [4,49,50]. Internali sa-
tion of SPIONs typically occurs by processes such as 
endo cytosis; that is, the engulfment of the SPIONs into 
the internal environment of the cells by receptor-media-
ted responses – for example, adsorptive endocytosis or 
the use of cell pene trating peptides/proteins (nonspeciﬁ c 
attachment) [30]. Th is method increases the local density 
of SPIONs [45,51] and is favoured for in vivo applications. 
Th e rate of internalisation depends on a number of 
factors, including cell type, particle size, hydrophobicity, 
surface charge of the particle polymer and the rate of cell 
proliferation [20]. Once internalised, within the cell, the 
SPIONs can be detected and/or manipulated through 
magnetism to yield a response [6]. It is important to note 
that through the proliferation of cells, the quantity of 
SPIONs relative to cell density diminishes during 
expansion of cells; that is, the dilution eﬀ ect [30]. 
Furthermore, exocytosis can potentially remove the 
SPIONs after internalisation [45]. Internalisation is 
achieved through the simple incubation of cells with the 
SPIONs, so evoking spontaneous uptake [28]. Th e 
particles are then localised within the endosomes of the 
cell and fused with lysosomes [30,50]. Th is method tends 
to be time consuming and is limited to cells that have a 
high degree of phagocytosis [52]. Figure 2 illustrates the 
mechanisms for the internalisation of SPIONs.
Cells exhibiting a low degree of phagocytosis may 
require prolonged incubation for eﬃ  cient internalisation 
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of SPIONs. Th is may be undesirable, as extended culture 
could impair the potency of the cells or redirect diﬀ er-
entiation towards an unwanted lineage [53]. Th e use of 
transfection agents can be employed to increase labelling 
eﬃ  ciency in a shorter period of time, as the agents can 
form complexes with superparamagnetic iron oxide, 
increasing uptake by phagocytosis [21,28]. Examples 
include poly-l-lysine, protamine and cationic liposomes 
[52]. Kostura and colleagues found that Feridex poly-l-
lysine in fact inhibited chondrogenesis, yet this was not 
found with Feridex protamine [54,55]. Th erefore, the 
eﬀ ect of the transfection agent must be investigated 
further as it may interfere with the activities of the cell 
[56]. To overcome the limitations incurred by internali-
sation and the use of transfection agents, a technique 
known as magneto electroporation has been introduced 
[30]. Essentially, a magnetic ﬁ eld is used to induce the 
accumulation of the contrast agent in the cytoplasm of 
the cell by increasing membrane permeability [52]. Th is 
eliminates the need for transfection agent antibodies, 
peptides and cell culturing all together [30], but unfortu-
nately the method is con sidered somewhat damaging to 
cells. Previous studies have shown that gene transfection 
can be improved using techniques such as 
magneto fection, which utilises the stimulation of MNPs 
(for exam ple, SPIONs) by a magnetic ﬁ eld to enhance the 
trans fection eﬃ  ciency of associated genes. Th is has been 
demon strated to be eﬀ ective both in vitro and in vivo 
[57,58].
Previous investigations have assessed the eﬀ ect of 
labelling cells with SPIONs on the diﬀ erentiation of stem 
cells [49]. Th e majority of these investigations report that 
SPIONs are frequently nontoxic to stem cells and do not 
aﬀ ect the diﬀ erentiation [54,59], proliferation, metabolic 
expression proﬁ le, reactive oxygen species formation and 
apoptosis rate [60]. A recent report by Balakumaran and 
colleagues using SPIONs and diﬀ erent contrast agents, 
includ ing ferumoxides, indicates that bone-marrow-
derived MSCs could retain their multipotentiality and 
could diﬀ erentiate to adipogenic, chondrogenic and 
osteo genic lineages [61]. Th is pro vides strong hope for 
the future of tracking and targeting stem cells in vivo to 
assess therapeutic applications.
Tracking, targeting and activation of 
SPION-labelled cells
Th e use of SPIONs in regenerative medicine is beneﬁ cial 
because they are multifunctional and can be used for the 
Figure 1. In vivo therapeutic applications of magnetic nanoparticles. Schematic diagram for the creation and functionalisation of the magnetic 
nanoparticles and the internalisation and implantation into stem cell labelling for magnetic resonance imaging (MRI) and fl uorescence tracking.
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tracking, targeting and activation of stem cells both in 
vivo and in vitro. Th ese aspects are now explored in 
greater detail.
Tracking
It is very diﬃ  cult to ﬁ nd the ideal combination of 
labelling agent and corresponding imaging tool that can 
successfully meet clinical needs. Th ere are many non-
invasive biological imaging devices commercially avail-
able, none of which are completely suited for the monitor-
ing and tracking of magnetically labelled stem cells to the 
accuracy and speciﬁ city needed. Th ese include MRI and 
magnetic resonance spectroscopy, which suﬀ er from low 
sensitivity but have high resolution (that is, 25 to 100 μm) 
[62]. Alternatively, positron emission tomography and 
bioluminescence imaging have higher sensitivity but 
lower resolution (that is, 1 to 2  mm) [62]. MRI is 
traditionally linked to the use of FDA-approved SPION-
based contrast agents and is typically the most applicable 
medical imaging tool for this speciﬁ c application because 
it is available in a vast majority of medical institutions [42]. 
Th is implies that the overall system is safe and thus requires 
little manipulation when used in regenerative medicine
Magnetic resonance imaging for tracking of SPION-loaded cells
Successful detection of SPION-labelled cells depends on 
the number of cells implanted, accumulation of iron in 
cells, spatial resolution of the image, the ﬁ eld strength of 
MRI, the signal:noise ratio and the pulse sequence 
[30,51]. Detection of SPIONs is attributed to the disrup tion 
of the magnetic ﬁ eld by the iron core. Th is disruption can 
be translated into a loss of signal and can be visualised as 
a hypointense region on T2 MRI sequences [48]. MRI has 
a resolution of about 25 to 100 μm resolution [62], which 
permits tracking of individual cells while still monitoring 
the surrounding anatomical struc tures. Th is ability is 
particularly useful for the clinician as information on the 
pathology of the surrounding tissue is a major issue when 
assessing the success of the therapy [4]. Furthermore, 
MRI allows for real-time correlation of cell localisation 
with corresponding, measurable physio logical outcomes 
[53]. Conversely, MRI lacks the ability to determine cell 
potency or the diﬀ erentiation state of the cells [51]. To 
tackle the limitations of traditional MRI techniques, a 
combination of various techniques has been suggested 
for tracking cells with SPIONs. Th e application of bi-
functional contrast agents is interesting as it allows 
multimodal imaging [42]; for example, incorporating an 
organic, ﬂ uorescent dye into a silica-coated shell of a 
particle with a magnetite core [50]. Th is bifunction ality 
oﬀ ers the combined beneﬁ ts of an iron-based contrast 
with the greater sensitivity of a ﬂ uorescent dye [40]. An 
example of one such agent is the multimodal nanoparticle 
MNPs@SiO2 (FITC), which has been shown to be a 
biocompatible contrast agent success ful in the labelling 
of MSC [47].
Th is use of MRI has shown great potential for in vitro 
studies [63], but currently the translation for the use of 
ﬂ uorescent dyes in clinical applications is limited as they 
cannot be detected in vivo. Th is clinical use may be 
Figure 2. Mechanisms for the internalisation of superparamagnetic iron oxide nanoparticles. Schematic diagram for the diff erent cellular 
uptake mechanisms of coated magnetic nanoparticles. Adapted from [45,92].
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possible in the near future, however, as iron oxide 
particles could be detected by MRI and the identiﬁ cation 
of ﬂ uorescent markers; for example, green ﬂ uorescent 
protein could be detected by near-infrared ﬂ uorescence 
imaging in vivo [64]. Furthermore, applying a combi nation 
of imaging tech niques such as positron emission tomo-
graphy, single-photon emission computed tomo graphy, 
ultrasound and optical imaging in conjunction with MRI 
may also provide more details regarding the behaviour of 
cells, while oﬀ ering excellent anatomical resolution [43] 
for advanced analysis of therapeutic eﬀ ect [59].
Targeting of magnetically labelled stem cells
Incorporating SPIONs into cells allows noncontact 
manipu lation of cells using an external magnetic ﬁ eld 
gradient. Th is can be used to precisely position or target 
the cells at the site for regeneration or repair [65,66], 
which is a powerful, non-invasive tool in stem cell 
therapy [67,68]. Importantly for orthopaedics, this tech-
nology has been applied in the vascularisation of various 
tissues by endothelial progenitor cells. Endothelial 
progenitor cells have a negatively charged surface, so they 
are capable of nonspeciﬁ c binding to anionic magnetic 
particles. Attaching magnetic particles to these cells does 
not aﬀ ect diﬀ erentiation or proliferation of the cells and 
also does not alter the membrane proteins that are essen-
tial for vascularisation [69]. Attaching magnetic particles 
to endothelial progenitor cells is thought to help in 
localised cell-based therapies as vascularisation is 
essential for the formation and development of many 
tissues. Directing these cells from a distance with an 
external magnetic ﬁ eld to areas that require vasculari-
sation can thus enhance the regeneration/repair for 
damaged tissues. Th e targeting of cells to a speciﬁ c site 
and monitoring their behaviour in a model system can 
therefore be examined and translated to in vivo studies 
[67]. Th is has recently been achieved by our group [70], 
whereby MSCs labelled with SPIONs could be trapped in 
a ﬂ uid ﬂ ow vessel in vitro, indicating that site-speciﬁ c 
targeting is possible. Th e positive data, based on a model 
system, led to an investigation for the implantation of a 
magnet subcutaneously to determine the potential for 
trapping and targeting labelled MSCs to a speciﬁ c 
location. We conﬁ rmed that site-speciﬁ c targeting was 
Figure 3. Cellular components contributing to mechano-transduction. Illustration of typical cellular interaction for mechanical translation, 
including intracellular, intercellular and extracellular matrix interactions and the potential stimulatory regulators based on those interactions. ECM, 
extracellular membrane. Adapted from [73].
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possible in vivo (manuscript submitted for publication). 
Th is ﬁ nding is highly promising, because once cells can 
be targeted to a speciﬁ c location the SPIONs bound to 
speciﬁ c cell membrane molecules (for example, ion 
channels or ligands) can be activated and manipulated.
Activation of stem cells using SPIONs
Mechanical stimulation can be used to facilitate cell 
diﬀ erentiation, proliferation and migration of stem cells 
[71]; physical forces include ﬂ uid ﬂ ow, axial compression, 
tension and magnetism [72]. Th is stimulation is achieved 
through mechano-transduction, which is the process 
whereby cells can convert physiological mechanical stimuli 
into biochemical signals [73]. Mechano-transduction can 
be subdivided into three separate areas: mechano-
coupling (mechanical trigger), cell–cell communication 
(distribution of the mechanical stimuli throughout a 
tissue) and the eﬀ ector response (that is, the response to 
that message  – for example, remodelling of the tissue) 
[74]. Attaching SPIONS to speciﬁ c cell surface receptors 
can induce various eﬀ ects when an external magnetic 
ﬁ eld is applied – for example, membrane stiﬀ ening, 
changes in the cell cytoskeleton (stiﬀ ening of actin 
ﬁ laments), Ca2+ inﬂ ux into the cells, mRNA and ribosome 
moving to focal adhesion complexes, increase in intra-
cellular cAMP, increase in CREB phosphorylation, increase 
in regulation in endothelin-1 expression and down stream 
activation of ion channels via FAK kinase [20,75]. Other 
changes also include regulation of mitogen-activated 
protein kinase activity, change in intracellular pH and 
increase in tyrosine phosphoregulation [72]. Further-
more, mechanical deformation of the cell membrane can 
directly activate mechano-sensitive ion channels. Th is 
has been shown to signiﬁ cantly aﬀ ect cell activity, 
enhancing the regenerative capabilities [20]. A variety of 
cellular components have been shown to contribute to 
mechano-transduction [73], as highlighted in Figure  3. 
Diﬀ erent receptors activate diﬀ erent path ways, but micro-
scopic and genetic techniques cannot identify which 
receptor initiates a cellular res ponse during mechano-
stimulation. Selective targeting of recep tors with MNPs 
circumvents the issues associated with macro scopic 
changes. Figure 4 highlights some of the ways to initiate a 
cellular response magnetically.
Figure 4. Diff erent mechanisms for mechanical stimulation using magnetic particles. Magnetic twisting cytometry: actin fi laments are 
stimulated by the attachment of large (1 μm) magnetic nanoparticles (MNPs) to integrin receptors on the cell membrane. A magnetic pulse is 
applied, followed by a torque being applied to the particle, resulting in a twisting motion. Mechano-sensitive (MS) ion channel activation: large 
MNPs are attached to the integrin. The magnetic force causes the particle to be pulled towards the fi eld, thus deforming the membrane and 
activating the adjacent MS ion channel. Targeted ion channel activation: MNPs (100 nm to 2.7 μm) are attached to certain MS ion channels via 
corresponding antibodies. Applying a magnetic force forces the channel to open. Receptor clustering: MNPs (30 nm) are bound to receptor 
complexes along the membrane, and once a force is applied with a magnetic needle the receptors are pulled towards the fi eld source, thus 
initiating receptor clustering. Adapted from [3].
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Clinical application of SPIONs in orthopaedics
Studies whereby SPIONs have been incorporated into 
various stem cell populations have yielded some interes-
ting data [30], especially with regard to animal models 
[4,76,77]. Initial proof of concept was demon strated in 
the early 1990s when immune cells were labelled with 
SPIONs. Th is gave conﬁ dence that the concept could be 
used for a range of cells and that cell migration could be 
monitored [78]. One universal issue is the inability to 
obtain large cell numbers for clinical applications. 
However, the use of magnetite cationic liposomes may be 
applied to overcome this [79]. Further more, this was used 
to create three-dimensional tissues without the need for 
scaﬀ old implantation. Human MSCs were labelled with 
20  pg/cell magnetite cationic liposomes (this concen-
tration was shown not to aﬀ ect diﬀ erentiation towards 
mesenchymal lineages). Th e cells were then placed in an 
ultralow attachment plate. A magnet was placed on the 
underside of the plate. Th is caused the cells to aggregate, 
forming a sheet. Cell sheets were then implanted into a 
cranial defect of female F344 rats. After 14  days, new 
bone formation was observed within the defect using the 
transplanted cell sheets. Th is was not the case with the 
control group; no bone formation was observed [80]. In a 
tracking study, the biodistribution of cells was assessed 
by labelling the cells with MNPs and monitoring their 
activity using MRI. Ex vivo studies were carried out with 
cartilage to determine the ability to track cells and 
diﬀ erentiate from surrounding cartilage. Insert ing 1,000 
cells into a 4  mm defect could not be detected. When 
10,000 and 100,000 cells were implanted, however, clear 
signals were observed and easily distinguishable from the 
surrounding cartilage [81]. Th ere are frequent examples 
of MNPs being used for bone tissue engineering [82,83]. 
MSCs were injected into a joint cavity to investigate the 
mechanism of cartilage repair with MSCs and to 
investigate the internal environment of the cavity and 
how this inﬂ uences diﬀ erentiation of certain lineages of 
MSC. With time, cells were found to have migrated to the 
marrow sinuses and the synovial ﬂ uid. In addition, cells 
Figure 5. Superparamagnetic iron oxide nanoparticles bind to RGD receptors on the surface of osteoblasts. Confocal laser scanning 
microscopy images of MG63 bone-like cells after (a), (b) 4 hours and (c), (d) 24 hours incubation with RGD-coated 2.7 μm ‘Flash red’ fl uorescent 
magnetic particles. The cytoplasm of viable cells is labelled with Calcein-AM (green). Reprinted from [85].
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did not migrate to the adjacent cartilage defects, perhaps 
due to strong collagen networks and the proteoglycan 
matrix [41].
In our laboratory we have demonstrated how SPIONs 
can be bound to RGD receptors on the surface of osteo-
blasts, enabling stimulation over a 3-week period (Figure 5). 
Following cyclical magnetic stimulation, labelled cells 
demonstrated upregulation of osteopontin (a key 
component in the diﬀ erentiation and activity of the bone 
cells and the maturation and mineralisation of the bone 
matrix), and increased osteo-related protein production 
[72]. Th ese results indicate that culture of SPIONs with 
osteoblasts does not inhibit osteogenic behaviour. 
Furthermore, SPIONs can be bound to selected membrane 
receptors and then subjected to oscillating magnetic 
ﬁ elds via a magnetic force bioreactor (MFB) in order to 
stimulate tagged receptors and provide mechano-trans-
duction through the cell membrane. Many cell-based 
therapies could beneﬁ t from this technology; however, 
the mechanical conditioning of the cells and the tissues 
in a bioreactor is a vital part in determining the tissues 
being produced. Th e MFB has been used in the 
production of bone and cartilage. MFBs have a particular 
advantage over traditional bioreactors in the sense that 
the MFB decreases the risk of infections as the reactor is 
operating within a closed system. Th e cells remain within 
the container in the speciﬁ c culture medium and the 
magnetic ﬁ eld is applied externally; this serves a dual 
purpose as the supply of nutrients to the cells is limited 
and not continuous in conventional bioreactors, which 
can be detrimental in the viability of a stem cell. Cells 
remain in the container, within a speciﬁ c culture 
medium, while an external magnetic force is applied. Th e 
supply of nutrients in this system is controlled, not 
continuously ﬂ owing. Th is eliminates sterility issues and 
also reduces the application of forces (for example, ﬂ uid 
shear stress), other than magnetic stimulation.. Secondly, 
the MFB provides a more spatial scalable system, making 
it the more attractive choice for tissue formation that is 
not possible with conventional systems. Furthermore, it 
is thought that in the MFB the mechanical stresses 
applied can be controlled by altering the strength of the 
Figure 6. Cell lines can be guided towards diff erent mesenchymal lineages for orthopaedic applications. Histological and 
immunohistochemistry staining of human bone marrow mesenchymal stem cells (HBMSC); HBMSC + transforming growth factor (TGF) β3, 
HBMSC labelled with TREK-1, or HBMSC labelled with RGD particles encapsulated in alginate/chitosan capsules and exposed to a pulsed magnetic 
fi eld for 21 days in vitro. Tissue sections (6 μm) were stained for sulphated mucins using Alcian blue and for collagen using (A to D) Sirius red, 
(E to H) collagen type 1 and (I to L) collagen type 2. Scale bars = 100 μm.
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magnet, the duration of the force applied and the distance 
from the cells. Lastly, the stress is applied to the cell 
membrane; there would be no need to ensure that the 
cells attach to a mechanically durable scaﬀ old.
Over recent years, our group has performed many 
investigations into the use of MFBs to stimulate stem cell 
diﬀ erentiation [84-89]. Mechanical force is known to have 
a direct eﬀ ect on the stimulation of stem cells. 
Furthermore, it was determined that speciﬁ c magnetic 
mechano-conditioning is required during stages of 
osteogenic diﬀ erentiation [88]. Th ese studies indicate that 
MNPs are useful for determining and stimulating speciﬁ c 
pathways related to the diﬀ erentiation of stem cells.
Remote diﬀ erentiation of stem cells is an exciting 
potential for magnetic particle technology in the ﬁ eld of 
tissue engineering, for multiple cell lineages [90]. Stem 
cell diﬀ erentiation in target repair tissues can be 
controlled in vivo through external cycling magnetic 
ﬁ elds. It is possible to attach MNPs to speciﬁ c ion 
channels; that is, TREK-1. Markers of osteogenic and 
chondrogenic diﬀ erentiation were investigated after 
activation of this channel. Th e expression of collagen type 
I, SOX9, RUNX2 and osteopontin mRNA increased, 
relative to the control samples. Furthermore, both in 
vitro and in vivo studies conﬁ rmed that expression of 
collagen types I and II and proteoglycan and collagen 
synthesis could be considerably enhanced using MNPs 
coated with RGD peptides [83]. Th ese results are there-
fore a strong indica tion that various cell lines, including 
MSCs, can be guided towards diﬀ erent mesenchymal 
lineages for ortho paedic applications (Figure 6) [87].
Conclusion
In orthopaedics, cell therapies are moving rapidly forward 
for routine use in clinical therapies [12]. Deﬁ ning the 
success of these therapies and identifying ways to 
improve and routinely replicate these clinical practices 
are required to enable further development for the clinic, 
as MNPs can provide information regarding the optimal 
route, dosage scheme and localisation and migration of 
cells for therapeutic treatments. Th e applications of 
MNPs in regenerative medicine are diverse, oﬀ ering a 
potential route to improve the way in which we can 
control, monitor and target stem cells to the sites of 
repair. A large number of in vitro studies have reported 
that iron-oxide-based MNPs do not aﬀ ect the viability, 
proliferation and diﬀ erentiation capacity of cells in vitro. 
However, long-term in vivo studies have not been studied 
as extensively. Successful integration of these techniques 
into surgical practice relies on building conﬁ dence in 
surgeons that nanoparticles are not harmful and can be 
used routinely in patients. Stem-cell-based therapies 
diﬀ er from conventional therapies (including pharma-
ceu ticals) in the sense that the cells are the active therapy 
and must remain in the body and integrate into the in 
vivo environment to have a therapeutic eﬀ ect. Research 
demonstrating the long-term stability and functional, 
therapeutic repair – both in vitro and in vivo – of the 
regulatory bodies is an exciting prospect and would pave 
the way for future clinical applications of nanoparticle-
based stem cell therapies [91]. Th e use of magnetic force, 
in the context of bioreactors, has proven to be an 
interesting area, permitting stimulation of targeted surface 
receptors (for example, ion channels). Th is broadens the 
scope for the use of MNPs in orthopaedic applications 
using stem cells, with particular regard to controlling 
diﬀ erentiation. Th ere is hope that the technique will 
make the translation from bench to bedside in the future. 
Clinical trials have shown no adverse side eﬀ ect of 
labelling stem cells with SPIONs. It is essential to conﬁ rm 
the safety of the procedure prior to in vivo transplantation 
and, despite clinical eﬃ  cacy for the technique, long-term 
evaluation of the safety of using MNPs is yet to be 
conducted [12,92].
Abbreviations
MFB, magnetic force bioreactor; MNP, magnetic nanoparticle; MRI, magnetic 
resonance imaging; MSC, mesenchymal stem cell; SPION, superparamagnetic 
iron oxide nanoparticle.
Competing interests
The authors declare that they have no competing interests.
Acknowledgements
The authors would like to thank SL Wilson and S Hughes for their contributions 
to this work. Support was received from Expertissues (NMP3-CT-2004-500283) 
and from the EPSRC Doctoral Training Centre (EP/F/500491/1).
Published: 19 April 2012
References
1. Mason C, Dunnill P: A brief defi nition of regenerative medicine. Regen Med 
2008, 3:1-5.
2. Hoehn M, Kustermann E, Blunk J, Wiedermann D, Trapp T, Wecker S, Focking 
M, Arnold H, Hescheler J, Fleischmann BK, Schwindt W, Buhrle C: Monitoring 
of implanted stem cell migration in vivo: a highly resolved in vivo 
magnetic resonance imaging investigation of experimental stroke in rat. 
Proc Natl Acad Sci U S A 2002, 99:16267-16272.
3. Dobson J: Remote control of cellular behaviour with magnetic 
nanoparticles. Nat Nanotechnol 2008, 3:139-143.
4. Berman SMC, Walczak P, Bulte JWM: Tracking stem cells using magnetic 
nanoparticles. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2011, 
3:343-355.
5. Riehemann K, Schneider SW, Luger TA, Godin B, Ferrari M, Fuchs H: 
Nanomedicine – challenge and perspectives. Angew Chem Int Ed Engl 2009, 
48:872-897.
6. Krishnan KM: Biomedical nanomagnetics: a spin through possibilities in 
imaging, diagnostics, and therapy. IEEE Trans Magn 2010, 46:2523-2558.
7. Pankhurst QA, Connolly J, Jones SK, Dobson J: Applications of magnetic 
nanoparticles in biomedicine. J Phys D Appl Phys 2003, 36:R167.
8. Banerjee R, Katsenovich Y, Lagos L, McIintosh M, Zhang X, Li CZ: 
Nanomedicine: magnetic nanoparticles and their biomedical applications. 
Curr Med Chem 2010, 17:3120-3141.
9. Barakat NS: Magnetically modulated nanosystems: a unique drug-delivery 
platform. Nanomedicine 2009, 4:799-812.
10. Lin M, Kim D, El Haj A, Dobson J: Development of superparamagnetic iron 
oxide nanoparticles (SPIONS) for translation to clinical applications. IEEE 
Trans Nanobioscience 2008, 7:298-305.
11. Ito A, Kamihira M: Tissue engineering using magnetite nanoparticles. Prog 
Wimpenny et al. Stem Cell Research & Therapy 2012, 3:13 
http://stemcellres.com/content/3/2/13
Page 10 of 12
Mol Biol Transl Sci 2011, 104:355-395.
12. Yildirimer L, Thanh NTK, Loizidou M, Seifalian AM: Toxicology and clinical 
potential of nanoparticles. Nano Today 2011, 6:585-607.
13. Ju S, Teng G, Zhang Y, Ma M, Chen F, Ni Y: In vitro labeling and MRI of 
mesenchymal stem cells from human umbilical cord blood. Magn Reson 
Imaging 2006, 24:611-617.
14. Mahmoudi M, Sant S, Wang B, Laurent S, Sen T: Superparamagnetic iron 
oxide nanoparticles (SPIONs): development, surface modifi cation and 
applications in chemotherapy. Adv Drug Deliv Rev 2011, 63:24-46.
15. Weissleder R, Stark DD, Engelstad BL, Bacon BR, Compton CC, White DL, 
Jacobs P, Lewis J: Superparamagnetic iron oxide: pharmacokinetics and 
toxicity. Am J Roentgenol 1989, 152:167-173.
16. Hofmann-Amtenbrink M, Hofmann H, Montet X: Superparamagnetic 
nanoparticles –a tool for early diagnostics. Swiss Med Wkly 2010, 140:7-13.
17. Berry CC: Possible exploitation of magnetic nanoparticle–cell interaction 
for biomedical applications. J Mater Chem 2005, 15:543-547.
18. Bean CP: Hysteresis loops of mixtures of ferromagnetic micropowders. 
J Appl Phys 1955, 26:1381-1383.
19. Getzlaff  M: Fundamentals of Magnetism. New York: Springer; 2008.
20. Hughes S, El Haj AJ, Dobson J: Magnetic micro- and nanoparticle mediated 
activation of mechanosensitive ion channels. Med Eng Phys 2005, 
27:754-762.
21. Solanki A, Kim JD, Lee K-B: Nanotechnology for regenerative medicine: 
nanomaterials for stem cell imaging. Nanomedicine 2008, 3:567-578.
22. Weissleder R, Elizondo G, Wittenberg J, Rabito CA, Bengele HH, Josephson L: 
Ultrasmall superparamagnetic iron oxide: characterization of a new class 
of contrast agents for MR imaging. Radiology 1990, 175:489-493.
23. Shen T, Weissleder R, Papisov M, Bogdanov A, Brady TJ: Monocrystalline iron 
oxide nanocompounds (MION): physicochemical properties. Magn Reson 
Med 1993, 29:599-604.
24. Long CM, Bulte JWM: In vivo tracking of cellular therapeutics using 
magnetic resonance imaging. Expert Opin Biol Ther 2009, 9:293-306.
25. Thorek D, Chen A, Czupryna J, Tsourkas A: Superparamagnetic iron oxide 
nanoparticle probes for molecular imaging. Ann Biomed Eng 2006, 34:23-38.
26. Gupta AK, Gupta M: Synthesis and surface engineering of iron oxide 
nanoparticles for biomedical applications. Biomaterials 2005, 26:3995-4021.
27. Pardoe H, Chua-anusorn W, St Pierre TG, Dobson J: Structural and magnetic 
properties of nanoscale iron oxide particles synthesized in the presence of 
dextran or polyvinyl alcohol. J Magn Magn Mater 2001, 225:41-46.
28. Bulte JWM: In vivo MRI cell tracking: clinical studies. Am J Roentgenol 2009, 
193:314-325.
29. van Buul GM, Farrell E, Kops N, van Tiel ST, Bos PK, Weinans H, Krestin GP, van 
Osch GJVM, Bernsen MR: Ferumoxides–protamine sulfate is more eff ective 
than ferucarbotran for cell labeling: implications for clinically applicable 
cell tracking using MRI. Contrast Media Mol Imaging 2009, 4:230-236.
30. Zhou R, Acton PD, Ferrari VA: Imaging stem cells implanted in infarcted 
myocardium. J Am Coll Cardiol 2006, 48:2094-2106.
31. Oakes BW: Orthopaedic tissue engineering: from laboratory to the clinic. 
Med J Aust 2004, 180:S35-S38.
32. Caplan AI: Mesenchymal stem cells: cell-based reconstructive therapy in 
orthopedics. Tissue Eng 2005, 11:1198-1211.
33. Vats A, Tolley NS, Buttery LDK, Polak JM: The stem cell in orthopaedic 
surgery. J Bone Jt Surg Br 2004, 86B:159-164.
34. Roberts S, Genever P, McCaskie A, De Bari C: Prospects of stem cell therapy 
in osteoarthritis. Regen Med 2011, 6:351-366.
35. Behrens P, Bitter T, Kurz B, Russlies M: Matrix-associated autologous 
chondrocyte transplantation/implantation (MACT/MACI) – 5-year follow-
up. Knee 2006, 13:194-202.
36. Tang C, Russell PJ, Martiniello-Wilks R, J. Rasko JE, Khatri A: Concise review: 
Nanoparticles and cellular carriers – allies in cancer imaging and cellular 
gene therapy? Stem Cells 2010, 28:1686-1702.
37. Yu MK, Jeong YY, Park J, Park S, Kim JW, Min JJ, Kim K, Jon S: Drug-loaded 
superparamagnetic iron oxide nanoparticles for combined cancer 
imaging and therapy in vivo. Angew Chem Int Ed Engl 2008, 47:5362-5365.
38. Derfus AM, Chan WCW, Bhatia SN: Intracellular delivery of quantum dots for 
live cell labeling and organelle tracking. Adv Mater 2004, 16:961-966.
39. Cheng K, Benten D, Bhargava K, Inada M, Joseph B, Palestro C, Gupta S: 
Hepatic targeting and biodistribution of human fetal liver stem/
progenitor cells and adult hepatocytes in mice. Hepatology 2009, 
50:1194-1203.
40. Liu W, Frank JA: Detection and quantifi cation of magnetically labeled cells 
by cellular MRI. Eur J Radiol 2009, 70:258-264.
41. Jing XH, Yang L, Duan XJ, Xie B, Chen W, Li Z, Tan HB: In vivo MR imaging 
tracking of magnetic iron oxide nanoparticle labeled, engineered, 
autologous bone marrow mesenchymal stem cells following intra-
articular injection. Joint Bone Spine 2008, 75:432-438.
42. Himmelreich U, Dresselaers T: Cell labeling and tracking for experimental 
models using magnetic resonance imaging. Methods 2009, 48:112-124.
43. Athiraman H, Jiang Q, Ding GL, Zhang L, Zhang ZG, Wang L, Arbab AS, Li Q, 
Panda S, Ledbetter K, Rad AM, Chopp M: Investigation of relationships 
between transverse relaxation rate, diff usion coeffi  cient, and labeled cell 
concentration in ischemic rat brain using MRI. Magn Reson Med 2009, 
61:587-594.
44. Tran LA, Krishnamurthy R, Muthupillai R, da Graca Cabreira-Hansen M, 
Willerson JT, Perin EC, Wilson LJ: Gadonanotubes as magnetic nanolabels 
for stem cell detection. Biomaterials 2010, 31:9482-9491.
45. Ferreira L: Nanoparticles as tools to study and control stem cells. J Cell 
Biochem 2009, 108:746-752.
46. Wu YL, Ye Q, Foley LM, Hitchens TK, Sato K, Williams JB, Ho C: In situ labeling 
of immune cells with iron oxide particles: an approach to detect organ 
rejection by cellular MRI. Proc Natl Acad Sci U S A 2006, 103:1852-1857.
47. Park KS, Tae J, Choi B, Kim YS, Moon C, Kim SH, Lee HS, Kim J, Kim J, Park J, Lee 
JH, Lee JE, Joh JW, Kim S: Characterization, in vitro cytotoxicity assessment, 
and in vivo visualization of multimodal, RITC-labeled, silica-coated 
magnetic nanoparticles for labeling human cord blood-derived 
mesenchymal stem cells. Nanomedicine 2010, 6:263-276.
48. Engberink RDO, van der Pol SMA, Walczak P, van der Toorn A, Viergever MA, 
Dijkstra CD, Bulte JWM, de Vries HE, Blezer ELA: Magnetic resonance imaging 
of monocytes labeled with ultrasmall superparamagnetic particles of iron 
oxide using magnetoelectroporation in an animal model of multiple 
sclerosis. Mol Imaging 2010, 9:268-277.
49. Lu CW, Hung Y, Hsiao JK, Yao M, Chung TH, Lin YS, Wu SH, Hsu SC, Liu HM, 
Mou CY, Yang CS, Huang DM, Chen YC: Bifunctional magnetic silica 
nanoparticles for highly effi  cient human stem cell labeling. Nano Lett 2006, 
7:149-154.
50. Sung C, Hong K, Lin S, Lee Y, Cha J, Lee J, Hong C, Han B, Jung S, Kim S, Yoon 
K: Dual-modal nanoprobes for imaging of mesenchymal stem cell 
transplant by MRI and fl uorescence imaging. Korean J Radiol 2009, 
10:613-622.
51. Ferreira L, Karp JM, Nobre L, Langer R: New opportunities: the use of 
nanotechnologies to manipulate and track stem cells. Cell Stem Cell 2008, 
3:136-146.
52. Dousset V, Tourdias T, Brochet B, Boiziau C, Petry KG: How to trace stem cells 
for MRI evaluation? J Neurol Sci 2008, 265:122-126.
53. Walczak P, Ruiz-Cabello J, Kedziorek DA, Gilad AA, Lin S, Barnett B, Qin L, 
Levitsky H, Bulte JWM: Magnetoelectroporation: improved labeling of 
neural stem cells and leukocytes for cellular magnetic resonance imaging 
using a single FDA-approved agent. Nanomed Nanotechnol Biol Med 2006, 
2:89-94.
54. Arbab AS, Yocum GT, Rad AM, Khakoo AY, Fellowes V, Read EJ, Frank JA: 
Labeling of cells with ferumoxides – protamine sulfate complexes does 
not inhibit function or diff erentiation capacity of hematopoietic or 
mesenchymal stem cells. NMR Biomed 2005, 18:553-559.
55. Kostura L, Kraitchman DL, Mackay AM, Pittenger MF, Bulte JWM: Feridex 
labeling of mesenchymal stem cells inhibits chondrogenesis but not 
adipogenesis or osteogenesis. NMR Biomed 2004, 17:513-517.
56. Yiu HHP, Maple MJ, Lees MR, Palona I, El Haj AJ, Dobson J: Preparation and 
characterization of iron oxide–silica composite particles using 
mesoporous SBA-15 silica as template and their internalization into 
mesenchymal stem cell and human bone cell lines. IEEE Trans 
Nanobioscience 2010, 9:165-170.
57. Scherer F, Anton M, Schillinger U, Henke J, Bergemann C, Krüger A, 
Gänsbacher B, Plank C: Magnetofection: enhancing and targeting gene 
delivery by magnetic force in vitro and in vivo. Gene Ther 2002, 9:102-109.
58. Plank C, Scherer F, Schillinger U, Bergemann C, Anton M: Magnetofection: 
enhancing and targeting gene delivery with superparamagnetic 
nanoparticles and magnetic fi elds. J Liposome Res 2003, 13:29-32.
59. Budde MD, Frank JA: Magnetic tagging of therapeutic cells for MRI. J Nucl 
Med 2009, 50:171-174.
60. Ito A, Hibino E, Honda H, Hata K-i, Kagami H, Ueda M, Kobayashi T: A new 
methodology of mesenchymal stem cell expansion using magnetic 
nanoparticles. Biochem Eng J 2004, 20:119-125.
Wimpenny et al. Stem Cell Research & Therapy 2012, 3:13 
http://stemcellres.com/content/3/2/13
Page 11 of 12
61. Balakumaran A, Pawelczyk E, Ren J, Sworder B, Chaudhry A, Sabatino M, 
Stroncek D, Frank JA, Robey PG: Superparamagnetic iron oxide 
nanoparticles labeling of bone marrow stromal (mesenchymal) cells does 
not aff ect their ‘stemness’. PLoS ONE 2010, 5:e11462.
62. Massoud TF, Gambhir SS: Molecular imaging in living subjects: seeing 
fundamental biological processes in a new light. Genes Dev 2003, 
17:545-580.
63. Huh YM, Jun YW, Song HT, Kim S, Choi JS, Lee JH, Yoon S, Kim KS, Shin JS, Suh 
JS, Cheon J: In vivo magnetic resonance detection of cancer by using 
multifunctional magnetic nanocrystals. J Am Chem Soc 2005, 
127:12387-12391.
64. Medarova Z, Pham W, Farrar C, Petkova V, Moore A: In vivo imaging of siRNA 
delivery and silencing in tumors. Nat Med 2007, 13:372-377.
65. Kyrtatos PG, Lehtolainen P, Junemann-Ramirez M, Garcia-Prieto A, Price AN, 
Martin JF, Gadian DG, Pankhurst QA, Lythgoe MF: Magnetic tagging 
increases delivery of circulating progenitors in vascular injury. J Am Coll 
Cardiol Cardiovasc Interv 2009, 2:794-802.
66. Ho VHB, Barcza A, Chen R, Müller KH, Darton NJ, Slater NKH: The precise 
control of cell labelling with streptavidin paramagnetic particles. 
Biomaterials 2009, 30:6548-6555.
67. Kim J, Lee H, Kang H-J, Park T: The targeting of endothelial progenitor cells 
to a specifi c location within a microfl uidic channel using magnetic 
nanoparticles. Biomed Microdevices 2009, 11:287-296.
68. Hsiao JK, Tai MF, Chu HH, Chen ST, Li H, Lai DM, Hsieh ST, Wang JL, Liu HM: 
Magnetic nanoparticle labeling of mesenchymal stem cells without 
transfection agent: cellular behavior and capability of detection with 
clinical 1.5 T magnetic resonance at the single cell level. Magn Reson Med 
2007, 58:717-724.
69. Wilhelm C, Bal L, Smirnov P, Galy-Fauroux I, Clément O, Gazeau F, Emmerich J: 
Magnetic control of vascular network formation with magnetically labeled 
endothelial progenitor cells. Biomaterials 2007, 28:3797-3806.
70. Sura HS, Magnay J, Attridge K, Zghoul N, Dobson J, El Haj AJ: Gene 
expression changes in stem cells following targeted localisation in a fl ow 
system using magnetic particle technology. ECM 2008, 16:18.
71. Sniadecki NJ: Minireview: A tiny touch: activation of cell signaling 
pathways with magnetic nanoparticles. Endocrinology 2010, 151:451-457.
72. Cartmell SH, Dobson J, Verschueren S, El Haj AJ: Development of magnetic 
particle techniques for long-term culture of bone cells with intermittent 
mechanical activation. Trans Nanobioscience 2002, 1:92-97.
73. Ingber DE: Cellular mechanotransduction: putting all the pieces together 
again. FASEB J 2006, 20:811-827.
74. Khan KM, Scott A: Mechanotherapy: how physical therapists’ prescription 
of exercise promotes tissue repair. Br J Sports Med 2009, 43:247-252.
75. Cartmell SH, Dobson J, Verschueren S, Hughes S, El Haj AJ: Mechanical 
conditioning of bone cells in vitro using magnetic micro particle 
technology. Eur Cells Mater 2002, 4(Suppl 2):130-131.
76. Bulte JWM, Duncan ID, Frank JA: In vivo magnetic resonance tracking of 
magnetically labeled cells after transplantation. J Cereb Blood Flow Metab 
2002, 22:899-907.
77. Cohen ME, Muja N, Fainstein N, Bulte JWM, Ben-Hur T: Conserved fate and 
function of ferumoxides-labeled neural precursor cells in vitro and in vivo. 
J Neurosci Res 2010, 88:936-944.
78. Bulte JW ML, Magin RL, Kamman RL, Hulstaert CE, Go KG, The TH, de Leij L: 
Selective MR imaging of labeled human peripheral blood mononuclear 
cells by liposome mediated incorporation of dextran-magnetite particles. 
Magn Reson Med 1993, 29:32-37.
79. Shimizu K, Ito A, Honda H: Mag-seeding of rat bone marrow stromal cells 
into porous hydroxyapatite scaff olds for bone tissue engineering. J Biosci 
Bioeng 2007, 104:171-177.
80. Shimizu K, Ito A, Yoshida T, Yamada Y, Ueda M, Honda H: Bone tissue 
engineering with human mesenchymal stem cell sheets constructed 
using magnetite nanoparticles and magnetic force. J Biomed Mater Res Part 
B: Appl Biomater 2007, 82B:471-480.
81. Farrell E, Wielopolski P, Pavljasevic P, Kops N, Weinans H, Bernsen MR, van 
Osch GJVM: Cell labelling with superparamagnetic iron oxide has no eff ect 
on chondrocyte behaviour. Osteoarthritis Cartilage 2009, 17:961-967.
82. Taylor EN, Webster TJ: Multifunctional magnetic nanoparticles for 
orthopedic and biofi lm infections. Int J Nanotechnol 2010, 8:21-35.
83. Kanczler J, Sura H, Magnay J, Oreff o R, Green D, Dobson J, El Haj AJ: 
Controlled diff erentiation of human bone marrow stromal cells using 
magnetic nanoparticle technology. Tissue Eng Part A 2010, 16:3241-3250.
84. Dobson J, Cartmell S, Keramane A, El Haj A: Principles and design of a novel 
magnetic force mechanical conditioning bioreactor for tissue 
engineering, stem cell conditioning, and dynamic in vitro screening. 
IEEE Trans Nanobioscience 2006, 5:173-177.
85. Hughes S, Dobson J, El Haj AJ: Magnetic targeting of mechanosensors in 
bone cells for tissue engineering applications. J Biomech 2007, 40:S96-S104.
86. Hughes S, El Haj AJ, Dobson J: Magnetic micro- and nanoparticle mediated 
activation of mechanosensitive ion channels. Med Eng Phys 2005, 
27:754-762.
87. Hu B, Yang Y, Dobson JP, El Haj AJ, Bader D: Mechanical conditioning using 
magnetic nanoparticles bound to PDGF receptors on HBMSCs promotes 
the smooth muscle alpha actin (SMA) expression. In 8th International 
Conference on Cell & Stem Cell Engineering (ICCE). Volume 30. Edited by 
Magjarevic R. Berlin: Springer; 2011:23-25.
88. Hu B, Yang Y, El Haj AJ: Mechanoreceptor activation via magnetic particle 
regulates diff erentiation of human bone marrow stromal cells. Histol 
Histopathol 2011, 26(Suppl 1):360.
89. Hughes S, McBain S, Dobson J, El Haj AJ: Selective activation of 
mechanosensitive ion channels using magnetic particles. J R Soc Interface 
2008, 5:855-863.
90. Yang L, Zhang L, Webster TJ: Nanobiomaterials: state of the art and future 
trends. Adv Eng Mater 2011, 13:B197-B217.
91. Rogers WJ, Meyer CH, Kramer CM: Technology insight: in vivo cell tracking 
by use of MRI. Nat Clin Pract Cardiovasc Med 2006, 3:554-562.
92. van Buul GM, Kotek G, Wielopolski PA, Farrell E, Bos PK, Weinans H, Grohnert 
AU, Jahr H, Verhaar JAN, Krestin GP, van Osch GJVM, Bernsen MR: Clinically 
translatable cell tracking and quantifi cation by mri in cartilage repair 
using superparamagnetic iron oxides. PLoS ONE 2011, 6:e17001.
doi:10.1186/scrt104
Cite this article as: Wimpenny I, et al.: Orthopaedic applications of 
nanoparticle-based stem cell therapies. Stem Cell Research & Therapy 2012, 
3:13.
Wimpenny et al. Stem Cell Research & Therapy 2012, 3:13 
http://stemcellres.com/content/3/2/13
Page 12 of 12
